A very small amount of research will tell you that, solely in...

A very small amount of research will tell you that, solely in its lead indication, Bisantrene should be able to generate over $5Bn per annum in revenue. A review of historic and the most recent trials will also let you know that Bisantrene works in its lead indication, does what it says and is safe.

Since the research report on the lead indication was published, the RAC team has identified that Bisantrene is not just cardio-protective and anti-cancer synergistic, it is also Multi-Organ protective. This will increase its revenue capacity in its primary indication (ie as a combo drug to improve and make safer doxorubicin) to well above $5Bn per annum.

We also know from the medical research that the RAC team knows the Mode of Action, and that Bisantrene is anti-cancer synergistic and cardio protective for other widely used anti-cancer treatments including the highest revenue drug Keytruda.

As an anti-Melanoma drug for example, Bisantrene has another $5Bn a year opportunity.

I could go on to list other opportunities, but the monkey brain that evolution placed in your head has probably already exploded at the "too good to be true" nature of these statements.

Taking just these two opportunities we have $10Bn per annum USD on a very conservative basis. At a 4x peak revenue basis we get a value of $US40Bn or $60Bn in our local currency; that's a share price of equivalent of $300 per share.

At a current share price of ~$1.40 I fail to see how these shares could be considered over-valued.

Even the former Chair thought it was worth $10 a share as a quick flip (I could never understand why he valued it so cheaply given that he openly agreed with the revenue figures in the Triangle Report).

So you can take JC's $10 low ball, or Hunterr's $30 moon shot, or my expectation of $50, or the reddy-reckoner revenue multiple from the research report of $300; at every turn this is massively good value ATM IMHO